Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05642429 · ClinicalTrials.gov registry record · Phase 1
Study of AV-1959D, an Amyloid Beta Vaccine
A Phase 1 study of Alzheimer Disease, sponsored by Institute for Molecular Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 6
- Study locations
NCT05642429: Active Phase 1 study of Alzheimer Disease, sponsored by Institute for Molecular Medicine.
NCT05642429 is a Phase 1 study of Alzheimer Disease that is active but no longer recruiting, run by Institute for Molecular Medicine. The registered enrollment target is 48 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05642429, a Phase 1 study of Alzheimer Disease, is active but no longer recruiting, sponsored by Institute for Molecular Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 6
- Study locations
Study Summary
Phase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL AV-1959D
Study Locations (6)
Florida
- University of South Florida - Tampa
- Alzheimer's Research and Treatment Center - Wellington
Arizona
- Banner Alzheimer's Institute - Phoenix
California
- Hoag Memorial Hospital - Newport Beach
Georgia
- Accel Research - Decatur
New Jersey
- Global Medical Institutes Princeton Medical Institute - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2026-11-07 |
| Phase | Phase 1 |
What the registry record for NCT05642429 still lists
NCT05642429 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05642429 lists 6 locations in 5 states (Florida, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT05642429 about?
NCT05642429 is a clinical study titled "Study of AV-1959D, an Amyloid Beta Vaccine". Phase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).
What is the current status of trial NCT05642429?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-02-27. Estimated completion is 2026-11-07.
What conditions does trial NCT05642429 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT05642429?
The interventions under investigation include: Placebo (BIOLOGICAL), AV-1959D (BIOLOGICAL).
Who is sponsoring clinical trial NCT05642429?
This trial is sponsored by Institute for Molecular Medicine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05642429 being conducted?
This trial has 6 study locations across Arizona, California, Florida, Georgia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05642429's enrollment target sits among peer trials
48 215th of 306 higher than 90 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI